Rahul Aggarwal

1/ Our NEW @CircAHA study, simultaneously published with #ESCCongress 🚨 We develop and validate the NEW #DOAC Score ➡️ A bleeding risk score for patients with #afib on DOACs ✅ We find our DOAC Score outperforms prior risk scores, including the HAS-BLED tinyurl.com/3fzr65jy

Terrific work by budding stars @nikhilpatelll @ashwin !! Check out our article in AJPC: sciencedirect.com/science/articl… Thankful to @DLBHATTMD and @RahulAggarwalMD for their guidance and @khurramn1 for the opportunity

Our study of AMIE at @BIDMC_Medicine is out! You can read about what we did in posts from my co-authors (including the Google post below). But I wanted to talk about some background for this study, and what I think are most interesting findings. 🧵⬇️ x.com/GoogleResearch…

Delighted to share: Prospective Study of Conversational Diagnostic AI in Ambulatory Primary Care @GoogleDeepMind @GoogleResearch @BIDMChealth – arxiv.org/pdf/2603.08448 research.google/blog/exploring… Like real medical training, we @GoogleDeepMind took a series of milestones on the way to performing these real-world clinical encounters: from passing medical licensing-style exams (rdcu.be/dgGfJ) to mirroring PCP skills in simulated consultation OSCEs (nature.com/articles/s4158…). Now, in partnership with @BIDMChealth, 100 patients engaged in a text-chat with our AI (AMIE) up to 5 days before their in-person PCP visit. AMIE took a comprehensive history and drafted a summary & differential diagnosis (DDx) for the PCP. It was carefully monitored by a physician ready to intervene based on strict safety criteria.

7/ Bottom line: AI has the potential to reshape every stage of clinical trials — from design to conduct. If deployed responsibly, it could accelerate discovery, lower costs, and bring therapies to patients faster. 💭 What do YOU see as the biggest barrier to AI adoption in clinical trials? Full review 🔗 onlinelibrary.wiley.com/doi/10.1111/ec… #ClinicalTrials #DigitalHealth #HealthTech #AI

6/7 ⚖️ Ethics & Governance are central. AI in trials must include: • Human-in-the-loop oversight • Transparent audit trails & version control • Continuous validation & drift monitoring • Equity-focused evaluation • Clear regulatory pathways (e.g., MDDT, ISTAND) AI is a tool — not a replacement for clinical judgment.

1/7 🧬Artificial intelligence could transform the clinical trial enterprise. Trials remain the gold standard of evidence generation — yet they are slow, costly & operationally complex. New review w/ @DLBhattMD in @EJCI_News examines how AI can reshape the trial lifecycle 🧵👇 🔗 onlinelibrary.wiley.com/doi/10.1111/ec… #ClinicalTrials #AIinMedicine

🚨New Viewpoint in @JAMA_current @CMSGov ACCESS launches July 2026, paying for outcomes across HTN, diabetes, CKM, behavioral health & more. In @JAMA_current, we break down promises & pitfalls. 🔗ja.ma/4tOxSSr ✨Team @Gong2Jingyi @LiuMichaelMD @RishiWadhera

New guest essay in the @nytimes: patients (and doctors) need to be open with each other about our AI use. It's here, it's useful (with drawbacks). If we put our heads in the sand, we get the dyadic "AI doctor" that cuts human relationships out of medicine …saging-custom-newsletters.nytimes.com/dynamic/render…

Excited to share our new piece just published in @NatureRevCards 🫀 A 2-year effort with a fantastic group of international experts across cardiology, interventional cardiology, and cardiac surgery. 🔗 nature.com/articles/s4156…

Our new @JACCJournals Cardiovascular Statistics annual report provides a clear-eyed understanding of cardiovascular health in the United States. Where we stand. Where we've made gains. And where we're falling behind. #JACCStats jacc.org/doi/10.1016/j.…

Excited to share our multimedia publication at @NEJMEvidence explaining what minimal clinically important difference means in statistical research. Thankful for the NEJM team and their mentorship! @ChanaSacks @JeffDrazen evidence.nejm.org/doi/full/10.10…

Honored to co-author a new @JACCJournals editorial with Dr. Peter Libby examining how mosaic loss of the Y chromosome (LOY) may shape cardiovascular risk in aging men and what it could mean for future research! 🔗Read our Editorial: lnkd.in/eYrBxMSR

Such a fun episode to write & co-host as an editorial fellow @NEJM ! We talk everything bugs, bacteremia & antibiotic duration on @COREIMpodcast #antibiotics #stewardship

How can we initiate therapies if patients are unaware of their diagnoses? We found that while 1 in 6 with cardiometabolic conditions have CKD, only 13% are aware. These gaps are the largest among women, younger adults and Hispanic adults. @JAMACardio jamanetwork.com/journals/jamac…

The PARTHENOPE Trial, which evaluated an individualized strategy of post-PCI antiplatelet therapy using the DAPT Score compared with standard of care, broke new ground on a number of fronts. @djc795, @EricSecemskyMD and I wrote about it in @JACCJournals. jacc.org/doi/10.1016/j.…

Using exam and lab data from NHANES, we found that treatment and control rates for common cardiovascular risk factors were similar in MA and TM @AndrewOseran @rkwadhera @RahulAggarwalMD #AHAJournals ahajrnls.org/4q7HOET